SCHEMBL7020692

SCHEMBL7020692

O=S(=O)(Cl)c1csc2ncccc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TRPV4 Q9HBA0 1/20 0.41
▸ MET P08581 1/20 0.36
▸ COMT P21964 1/20 0.35
▸ FTO Q9C0B1 1/20 0.35
▸ KAT2B Q92831 4/20 0.35
▸ EP300 Q09472 2/20 0.35
▸ CREBBP Q92793 2/20 0.35
▸ KAT2A Q92830 2/20 0.35
▸ LMNA P02545 2/20 0.35
▸ ALOX15 P16050 2/20 0.35
▸ TP53 P04637 1/20 0.35
▸ TSHR P16473 1/20 0.35
▸ OPRK1 P41145 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ NPSR1 Q6W5P4 1/20 0.35
▸ TLR9 Q9NR96 1/20 0.35
▸ TDP1 Q9NUW8 1/20 0.35
▸ IKBKB O14920 1/20 0.34
▸ CHUK O15111 1/20 0.34
▸ LIMK1 P53667 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7021189 0.83 FTO (0.49) METCOMTFTOLMNAALOX15
SCHEMBL27035950 0.72 — —
SCHEMBL23568561 0.72 TRPV4 (0.41) TRPV4COMTFTOALOX15NPSR1
SCHEMBL3971484 0.72 KDM4E (0.40) KAT2BEP300CREBBPKAT2ALMNA
SCHEMBL31252939 0.72 KDM4E (0.40) KAT2BEP300CREBBPKAT2ALMNA
SCHEMBL26978104 0.71 — —
SCHEMBL29469856 0.71 CA1 (0.47) TDP1ALDH1A1
SCHEMBL288542 0.71 CA1 (0.47) TDP1ALDH1A1
SCHEMBL7017726 0.70 EDNRA (0.56) —
SCHEMBL2176528 0.70 AXL (0.42) KAT2BEP300CREBBPKAT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0898571-B1 THIENO-PYRIDINE SULFONAMIDES, DERIVATIVES THEREOF AND RELATED COMPOUNDS THAT MODULATE THE ACTIVITY OF ENDOTHELIN ENCYSIVE PHARMACEUTICALS INC (US) 2003-11-19 — — EP disclosed
US-6545014-B2 Glaucoma; adjusting concentration of nitric oxide; hypotensive, antispasmodic, antiischemic, cardiotonic agents; bronchodilators; urogentital disorders; agonists, antagonists for endothelin receptors TEXAS BIOTECHNOLOGY CORPORATION 2003-04-08 — — US disclosed
US-20020028829-A1 Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin ENCYSIVE PHARMACEUTICALS INC. 2002-03-07 — — US disclosed
US-6329387-B2 ANTIHISTAMINE, ANTIINFLAMMATORY AGENTS, VISION DEFECTS TEXAS BIOTECHNOLOGY CORPORATION. 2001-12-11 — — US disclosed
US-20010014684-A1 THIENO-PYRIDINE SULFONAMIDES DERIVATIVES THEREOF AND RELATED COMPOUNDS THAT MODULATE THE ACTIVITY OF ENDOTHELIN ENCYSIVE PHARMACEUTICALS INC. 2001-08-16 — — US disclosed
US-6013655-A HYPOTENSIVE AGENTS; RESPIRATORY SYSTEM DIISORDERS TEXAS BIOTECHNOLOGY CORPORATION (US) 2000-01-11 — — US disclosed
EP-0898571-A1 THIENO-PYRIDINE SULFONAMIDES, DERIVATIVES THEREOF AND RELATED COMPOUNDS THAT MODULATE THE ACTIVITY OF ENDOTHELIN TEXAS BIOTECHNOLOGY CORPORATION (US) 1999-03-03 — — EP disclosed
WO-1997039000-A1 THIENO-PYRIDINE SULFONAMIDES, DERIVATIVES THEREOF AND RELATED COMPOUNDS THAT MODULATE THE ACTIVITY OF ENDOTHELIN TEXAS BIOTECHNOLOGY CORPORATION (US) 1997-10-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020028829-A1 Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin EDNRB, EDNRA, AGTR2 TRPV4 250/4885MET 858/4885COMT 4642/4885
US-20010014684-A1 THIENO-PYRIDINE SULFONAMIDES DERIVATIVES THEREOF AND RELATED COMPOUNDS THAT MODULATE THE ACTIVITY OF ENDOTHELIN EDNRB, EDNRA, AGTR1 TRPV4 429/4885MET 743/4885COMT 4558/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback